|D011024||Pneumonia, Viral NIH||0.11|
There is one clinical trial.
This is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with COVID-19. This clinical study aims to evaluate efficacy of anti-PD1 antibody in relation to viral clearance and its safety.
Description: Viral load changes in NPS based on SARS-CoV-2 RT-PCRMeasure: Viral clearance kinetics Time: From diagnosis to recovery, assessed up to 6 months
Description: Incidence and severity of treatment-related adverse eventsMeasure: Treatment-related adverse events of nivolumab (Intervention arm only) Time: Up to 1 year after nivolumab dosing
Description: Changes in lymphocyte countsMeasure: Lymphocyte kinetics Time: On days 1, 4, 6, 8, 10 and 28 from study enrollment
Description: Changes in cytokine levels (e.g. IL-1B, IL-2, IL-6, TNFa)Measure: Cytokine kinetics Time: On days 1, 4, 6, 8 and 10 from study enrollment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports